IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666

IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.32 B‬USD
−1.496USD
‪−444.04 M‬USD
‪1.19 M‬USD
‪247.04 M‬
Beta (1Y)
2.33
Employees (FY)
557
Change (1Y)
+54 +10.74%
Revenue / Employee (1Y)
‪2.13 K‬USD
Net income / Employee (1Y)
‪−797.19 K‬USD

About Iovance Biotherapeutics, Inc.


CEO
Frederick G. Vogt
Headquarters
San Carlos
Founded
2007
FIGI
BBG00JVRNSS7
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0JDK is 7.420 USD — it has increased by 0.39% in the past 24 hours. Watch IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 stocks are traded under the ticker 0JDK.
0JDK stock has fallen by −4.87% compared to the previous week, the month change is a −14.52% fall, over the last year IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 has showed a −9.97% decrease.
We've gathered analysts' opinions on IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 future price: according to them, 0JDK price has a max estimate of 34.00 USD and a min estimate of 10.00 USD. Watch 0JDK chart and read a more detailed IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 stock forecast: see what analysts think of IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 and suggest that you do with its stocks.
0JDK reached its all-time high on Jan 12, 2021 with the price of 51.270 USD, and its all-time low was 3.220 USD and was reached on Oct 19, 2023. View more price dynamics on 0JDK chart.
See other stocks reaching their highest and lowest prices.
0JDK stock is 2.75% volatile and has beta coefficient of 2.33. Track IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 stock price on the chart and check out the list of the most volatile stocks — is IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 there?
Today IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 has the market capitalization of ‪2.32 B‬, it has decreased by −4.48% over the last week.
Yes, you can track IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 financials in yearly and quarterly reports right on TradingView.
IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
0JDK earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.30 USD resulting in a 6.31% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 earnings.
IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 revenue for the last quarter amounts to ‪58.55 M‬ USD, despite the estimated figure of ‪53.79 M‬ USD. In the next quarter, revenue is expected to reach ‪71.51 M‬ USD.
0JDK net income for the last quarter is ‪−83.54 M‬ USD, while the quarter before that showed ‪−97.10 M‬ USD of net income which accounts for 13.96% change. Track more IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 financial stats to get the full picture.
No, 0JDK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 557.00 employees. See our rating of the largest employees — is IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 EBITDA is ‪−388.32 M‬ USD, and current EBITDA margin is ‪−35.95 K‬%. See more stats in IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 financial statements.
Like other stocks, 0JDK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 stock shows the sell signal. See more of IOVANCE BIOTHERAPEUTICS INC COM USD0.000041666 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.